A ruptured recurrent small bowel gastrointestinal stromal tumour causing hemoperitoneum

Eric C.H. Lai, Kam Man Chung, Stephanie H.Y. Lau, Wan Yee Lau

PDF(732 KB)
PDF(732 KB)
Front. Med. ›› 2015, Vol. 9 ›› Issue (1) : 108-111. DOI: 10.1007/s11684-014-0344-0
CASE REPORT
CASE REPORT

A ruptured recurrent small bowel gastrointestinal stromal tumour causing hemoperitoneum

Author information +
History +

Abstract

Hemoperitoneum is a rare and potentially life-threatening complication of GIST. We reported a 54-year-old man who developed disseminated intra-abdominal recurrence from a previously resected gastrointestinal stromal tumour (GIST) of the small bowel, and the patient presented with hemoperitoneum. Emergent debulking surgery was performed. A high dose imatinib was prescribed. Despite the presence of residual disease, the patient was well clinically 8 months after the operation. Even though, there is no evidence to support the routine use of debulking surgery in the management of GIST. In our patient, disease progression after second line targeted therapy and the absence of alternative treatment options for spontaneous rupture and hemoperitoneum prompted us to treat the patient aggressively. Resection of the ruptured GIST was carried out for control of bleeding and to prevent recurrent bleeding in this patient with good surgical risks. During the treatment decision-making, the patient’s general condition, the risk of surgery and the extent of dissemination were taken into consideration. In this patient who presented with spontaneous rupture of a small intestinal GIST, the novel use of targeted therapy and aggressive surgical treatment produced reasonably good survival outcome.

Keywords

gastrointestinal stromal tumour / hemoperitoneum / small bowel GIST / small bowel neoplasm / imatinib

Cite this article

Download citation ▾
Eric C.H. Lai, Kam Man Chung, Stephanie H.Y. Lau, Wan Yee Lau. A ruptured recurrent small bowel gastrointestinal stromal tumour causing hemoperitoneum. Front. Med., 2015, 9(1): 108‒111 https://doi.org/10.1007/s11684-014-0344-0

References

[1]
Lai EC, Lau SH, Lau WY. Current management of gastrointestinal stromal tumors—a comprehensive review. Int J Surg2012; 10(7): 334–340
CrossRef Pubmed Google scholar
[2]
Sorour MA, Kassem MI, Ghazal AH, El-Riwini MT, Abu Nasr A. Gastrointestinal stromal tumors (GIST) related emergencies. Int J Surg2014; 12(4): 269–280
CrossRef Pubmed Google scholar
[3]
Marano L, Antonio Arru GM, Piras M, Gemini S. Surgical management of acutely presenting gastrointestinal stromal tumors of the stomach among elderly: Experience of an emergency surgery department. Int J Surg. 2014 May 22. [Epub ahead of print] doi: 10.1016/j.ijsu.2014.05.025
Pubmed
[4]
Hirasaki S, Fujita K, Matsubara M, Kanzaki H, Yamane H, Okuda M, Suzuki S, Shirakawa A, Saeki H. A ruptured large extraluminal ileal gastrointestinal stromal tumor causing hemoperitoneum. World J Gastroenterol2008; 14(18): 2928–2931
CrossRef Pubmed Google scholar
[5]
Mahmoud A, Fadhel F, Amin M, Wael R, Amin D, Haykel B, Faouzi C, Rachid K, Mohamed J, Montasser K, Zoubeir BS. A ruptured ileal GI stromal tumor causing hemoperitoneum. Gastrointest Endosc2010; 71(1): 185–186, discussion 186
CrossRef Pubmed Google scholar
[6]
Pantaleo MA, Di Battista M, Catena F, Astorino M, Saponara M, Di Scioscio V, Santini D, Piazzi G, Castellucci P, Brandi G, Biasco G. Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib? J Cancer Res Clin Oncol2008; 134(5): 625–630
CrossRef Pubmed Google scholar
[7]
Tielen R, Verhoef C, van Coevorden F, Gelderblom H, Sleijfer S, Hartgrink HH, Bonenkamp JJ, van der Graaf WT, de Wilt JH. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib. Eur J Surg Oncol2013; 39(2): 150–155
CrossRef Pubmed Google scholar
[8]
Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Nguyen BP, Kerst M, Fiore M, Nyckowski P, Hoiczyk M, Cats A, Casali PG, Treckmann J, van Coevorden F, Gronchi A. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib — analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol2014; 40(4): 412–419
CrossRef Pubmed Google scholar
[9]
Pantaleo MA, Di Battista M, Catena F, Astorino M, Saponara M, Di Scioscio V, Santini D, Piazzi G, Castellucci P, Brandi G, Biasco G. Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib? J Cancer Res Clin Oncol2008; 134(5): 625–630
CrossRef Pubmed Google scholar
[10]
Ruka W, Rutkowski P, Szawłowski A, Nowecki Z, Debiec-Rychter M, Grzesiakowska U, Dziewirski W, Siedlecki JA, Michej W. Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib. Eur J Surg Oncol2009; 35(1): 87–91
CrossRef Pubmed Google scholar
[11]
Mullady DK, Tan BR. A multidisciplinary approach to the diagnosis and treatment of gastrointestinal stromal tumor. J Clin Gastroenterol2013; 47(7): 578–585
CrossRef Pubmed Google scholar

RIGHTS & PERMISSIONS

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg
AI Summary AI Mindmap
PDF(732 KB)

Accesses

Citations

Detail

Sections
Recommended

/